By Dean Seal
Shares of PTC Therapeutics fell after the company said regulators for the European Union won't renew authorization for its Translarna treatment for nonsense mutation Duchenne muscular dystrophy.
The stock was down 9% at $50 ahead of the market open on Friday. Shares had gained 22% year-to-date when the market closed yesterday. They were trading at $29.09 this time a year ago.
The Warren, N.J., company said before the bell that the European Commission adopted the opinion of the Committee for Medicinal Products for Human Use to remove the drug's conditional marketing authorization in the European Economic Area.
Still, the commission said individual countries within the European Union can use certain exemptions to continue using Translarna.
Chief Executive Matthew Klein said the decision is disappointing after a prolonged period of review by the European Commission.
"We look forward to working on a country-by-country basis to provide the commercial drug where possible," he said.
Write to Dean Seal at dean.seal@wsj.com
(END) Dow Jones Newswires
March 28, 2025 09:31 ET (13:31 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。